Which drug is generally avoided in Congestive Heart Failure due to negative inotropy effect?

Diltiazem is a non-dihydropyridine calcium channel blocker that exerts a significant negative inotropic effect, meaning it reduces the force of myocardial contraction. In congestive heart failure (CHF), the heart is already struggling to pump sufficient blood forward; adding a medication that further reduces contractility can precipitate acute decompensation and worsen outcomes. For this reason, diltiazem and verapamil are generally avoided in patients with reduced ejection fraction heart failure. Metoprolol succinate and carvedilol are beta-blockers that, paradoxically, are cornerstones of chronic stable CHF management. Although beta-blockers also have negative inotropic properties, they are introduced at low doses in stable patients to reduce sympathetic overdrive, lower heart rate, and remodel the myocardium over time, improving long-term survival. Their use is evidence-based and guideline-recommended in CHF with reduced ejection fraction. Valsartan is an angiotensin receptor blocker (ARB) that reduces afterload and preload by blocking angiotensin II, and it is also a guideline-directed therapy in CHF. The key distinction is that diltiazem's calcium channel blockade in cardiac tissue impairs systolic function without the compensatory benefits seen with beta-blockers, making it the drug to avoid in this setting.